February 9, 2018 / 12:01 AM / 10 months ago

BRIEF-Amgen Announces Phase 3 Xgeva Study Results

Feb 8 (Reuters) - Amgen Inc:

* RESULTS FROM PHASE 3 XGEVA® (DENOSUMAB) STUDY IN PATIENTS WITH MULTIPLE MYELOMA PUBLISHED IN LANCET ONCOLOGY

* AMGEN INC SAYS SAFETY PROFILE WAS CONSISTENT WITH KNOWN ADVERSE EVENTS OF BOTH XGEVA AND ZOLEDRONIC ACID

* AMGEN INC SAYS IN THIS STUDY, XGEVA SUCCESSFULLY MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below